Immune Systems Advisor

Mayumi Matsuda et al. Immunological Medicine Published online: 16 Apr 2024 PMID:  38627989 Abstract  Vaccines against coronavirus disease 2019 (COVID-19) have been distributed in most countries for the prevention of onset and aggravation of COVID-19. Recently, there have been increasing numbers of reports on new-onset autoimmune and autoinflammatory diseases following COVID-19 vaccination, however, only little information is available on the long-term safety of these vaccines. Here, we experienced three cases of new-onset rheumatic diseases following COVID-19 vaccination, one case each of rheumatoid arthritis (RA), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and systemic lupus erythematosus (SLE). The symptom onset ranged from one day to a few days following vaccination. The patients of AAV and SLE were treated successfully with glucocorticoid therapy, and the patient of RA died due to COVID-19. In the literature review of new-onset rheumatic diseas...

Abstract Background: Repurposed antiparasitic drugs ivermectin and mebendazole have been evaluated as therapeutic options for COVID-19 due to their antiviral and immunomodulatory potentials. Objectives: To synthesize the most recent, high-quality evidence on the efficacy and safety of ivermectin and mebendazole for COVID-19, including extensive real-time meta-analytic and controlled trial data. Methods: Narrative review integrating the July 2025 c19ivm.org meta-analysis (>220,000 patients), recent rigorous systematic reviews, observational data, and a phase II randomized placebo-controlled trial for mebendazole. Results: Ivermectin demonstrates significant reductions in mortality and severe outcomes in large, real-time meta-analyses—especially with prophylactic and early use, though recent systematic reviews raise questions about late-stage benefit. Mebendazole exhibits biological plausibility and early evidence for improved inflammation resolution and viral clearance, as shown in a...